HTG Molecular Diagnostics Inc Stock Nasdaq
Equities
Advanced Medical Equipment & Technology
End-of-day quote
Other stock markets
|
||
- | - |
2023 | Motion for De Minimus Asset Sale Approved for HTG Molecular Diagnostics, Inc. | CI |
2023 | Motion for De Minimus Asset Sale Filed by HTG Molecular Diagnostics, Inc. | CI |
Sales 2021 | 8.91M 0 | Sales 2022 | 6.37M 0 | Capitalization | 3.67M 0 |
---|---|---|---|---|---|
Net income 2021 | -17M - | Net income 2022 | -21M - | EV / Sales 2021 | 3.96 x |
Net cash position 2021 | 5.74M 0 | Net cash position 2022 | 3.41M 0 | EV / Sales 2022 | 0.04 x |
P/E ratio 2021 |
-2.19
x | P/E ratio 2022 |
-0.16
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 98% |
Managers | Title | Age | Since |
---|---|---|---|
John Lubniewski
CEO | Chief Executive Officer | 60 | 11-03-31 |
Shaun McMeans
DFI | Director of Finance/CFO | 62 | 12-01-31 |
Chief Administrative Officer | 45 | 14-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 66 | 15-10-26 | |
Director/Board Member | 59 | 22-01-26 | |
Ann Hanham
CHM | Chairman | 71 | 16-08-28 |
1st Jan change | Capi. | |
---|---|---|
-48.09% | 2.59B | |
+4.82% | 1.61B | |
-12.79% | 1.43B | |
+22.29% | 1.22B | |
-14.90% | 979M | |
-23.61% | 880M | |
-9.43% | 718M | |
-17.46% | 687M | |
+3.77% | 474M |